Extended Data Fig. 8. Combination of LC and PD-1 antibody results in greater anti-tumor effects.
a-b, MC38 or 4T1 tumor growth (n = 9 mice in MC38 tumor, n = 10 mice in 4T1 mice) and survival (n = 10 mice) of C57BL/6J or BALB/c mice gavaged with LC once per 2 days and treated with a total of 10 μg of anti-αPD-1 antibodies once per 2 days for 10 days. c, Percentage of infiltrating CD8+ T cells in MC38 or 4T1 tumor, IFN-γ+ and CD107a+ cells in CD8+ TILs at day 20 post tumor injection in mice. n = 6 mice. Data are presented as mean±s.e.m. P values were calculated using one-way ANOVA for Dunnett’s multiple comparisons test (c), two-way ANOVA for Tukey’s multiple comparisons test (a), Log-rank test for survival analysis and corrected by Bonferroni methods (b), ns (not significant).